Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study

Chinese RCT reported reduced rate of grade 2-4 acute graft-versus-host disease (GVHD) at day 100 in the antithymocyte globulin group vs controls (n=263; 13.7% vs 27.0%; P = 0.007) with lower incidences of 2-year overall chronic GVHD and 2-year extensive chronic GVHD.


Journal of Clinical Oncology